Videos

Raajit K. Rampal, MD, PhD, discusses the established role of JAK inhibition for the treatment of myelofibrosis.

Jeff Auletta, MD, discusses findings from a study evaluationg posttransplant cyclophosphamide in unmatched stem cell transplants.

Rebecca A. Shatsky, MD, discusses the advantages of giving patients with HER2-positive breast cancer a subcutaneous injection of targeted therapy compared with the intravenous formulation of trastuzumab and pertuzumab.

Hatem Soliman, MD, highlights the crucial role of HER2 targeting and staying informed about evolving treatment options for better patient outcomes in the HER2-positive breast cancer space.

Provide perspective on quality-of-life observations with different IO-TKI regimens and supporting evidence.

Dr. Hammers outlines his thought process around TKI/ICI dose modifications vs discontinuations with toxicity and discusses toxicity management recommendations.

Lori J. Wirth, MD, discusses imaging techniques, biomarker identification, and promising treatments on the horizon in the thyroid cancer space.

Discuss emerging data and therapies to optimize future treatment.

Dr. Plimack provides a brief overview of the prevalence of non-clear cell renal cell carcinoma and a short description of their subtypes.

Dr. Motzer discusses his view on the appropriateness of the initial therapy for this nccRCC patient, including key factors he considers when deciding on initial treatment.

Dr. Motzer provides his perspective on the notable aspects of this nccRCC case and how it compares to typical cases.

Adam Binder, MD, discusses how to handle gastrointestinal toxicities for patients with relapsed/refractory multiple myeloma who are on the triple therapy of selinexor, bortezomib, and dexamethasone.

Patrick Forde, MBBCh, and Tina Cascone, MD, PhD, give final thoughts on unmet needs in the non-small cell lung cancer space to inform future treatment strategies.

The panel discusses the future of ctDNA in clinical practice as well as sequencing decisions that may lead to adjuvant therapy in addition to neoadjuvant and/or perioperative therapy.

Marcia S. Brose, MD, PhD, FASCO, discusses potential next steps for approaching and treating patients with advanced or metastatic RET-mutant thyroid cancer.

Kayla Giannetti, MSN, APRN-CNP, discusses a study presented at the 2024 Transplantation and Cellular Therapy Tandem Meetings investigating the link between patient frailty and stem cell transplants.

Rebecca A. Shatsky, MD, discusses the outcomes of the phase 3 FeDeriCa study of subcutaneous trastuzumab and pertuzumab in patients with HER2-positive breast cancer.

Patrick Forde, MBBCh, and Tina Cascone, MD, PhD, discuss their institution’s approaches to treatment decision making for patients with resectable non-small cell lung cancer.

Medical professionals discuss perspectives on CheckMate-77T trial results and potential impacts on clinical practice.

Dr. Hammers shares his experience with high-grade AEs in IO-TKI treated patients and how toxicities are mitigated/managed.

Dr. Hammers explains factors involved in decision-making between immunotherapy-based treatment options.

Valentina Ardila, MD, discusses findings from a study investigating the role of obesity in patients undergoing stem cell transplants.

Raajit K. Rampal, MD, PhD, discusses the MANIFEST-2 trial, a phase 3 study comparing ruxolitinib vs pelabresib and ruxolitinib combined with placebo for the treatment of myelofibrosis.

Experts review the NEOTORCH study of 400 patients showing favorable outcomes with a hazard ratio for event-free survival of 0.4.

Tina Cascone, MD, PhD, analyzes results from the AEGEAN trial evaluating perioperative immunotherapy in stage II-IIIB non-small cell lung cancer.

Alice Bertaina, MD, discusses combining of T-allo10, a donor-derived cell product, with haploidentical stem cell transplants for the treatment of pediatric and young adult patients with hematologic malignancies.

Overview of side effects and management when combining these agents.

Highlight key findings in the KRYSTAL-7 trial.

Patrick Forde, MBBCh, discusses CheckMate-816 study results, including the high pathological complete response rates within 6 weeks of immunotherapy reported in the trial's third arm.

Patrick Forde, MBBCh, and Tina Cascone, MD, PhD, discuss personalized treatment approaches for non-small cell lung cancer tailored to individual patient needs and goals.